Patients with SARD-ILD-PPF who continued nintedanib for 12 months or longer had better outcomes than those who discontinued therapy.

Individuals with a history of immune-mediated inflammatory diseases (IMIDs) may have a higher risk for sarcoidosis onset, a Japanese study found.

Elexacaftor/tezacaftor/ivacaftor use is linked to long-term decreases in chronic respiratory therapies in patients with cystic fibrosis.

A pulmonologist is sued after responding to a call from ICU staff to prevent airway collapse in a patient who was ultimately left disabled.

Abortion will stay legal in Wyoming after the state Supreme Court ruled that abortion bans passed by lawmakers violate the state constitution.

Novo Nordisk announced the availability of Wegovy tablets, the first oral GLP-1 receptor agonist for weight loss and CV risk reduction.